Compare ALM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALM | OCS |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Canada | Switzerland |
| Employees | N/A | 3 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | ALM | OCS |
|---|---|---|
| Price | $14.05 | $24.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $22.33 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 6.2M | 352.6K |
| Earning Date | 03-18-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $583.67 | $466.06 |
| Revenue Next Year | $90.33 | $502.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $14.00 |
| 52 Week High | $22.55 | $30.68 |
| Indicator | ALM | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 40.05 |
| Support Level | $5.32 | $19.00 |
| Resistance Level | $14.92 | $29.19 |
| Average True Range (ATR) | 1.62 | 1.25 |
| MACD | -0.78 | -0.20 |
| Stochastic Oscillator | 1.06 | 17.11 |
Almonty Industries Inc is engaged in the mining, processing, and shipping of tungsten concentrate from its Los Santos tungsten mine located near Salamanca, Spain - the Los Santos Mine, the processing and shipping of tungsten concentrate from its Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal - the Panasqueira Mine, the evaluation of its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora - the Valtreixal Mine, as well as the exploration and evaluation of its Sangdong tungsten mine project located in Gangwon Province, Republic of Korea - the Sangdong Mine.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.